HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a $90 price target.
June 24, 2024 | 5:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Viking Therapeutics and maintained a $90 price target.
The reiteration of a Buy rating and a high price target of $90 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100